PsychoGenics and Cephalon have entered into a drug discovery agreement. Cephalon will supply compounds that are prospectively suitable for neuropsychiatric disorders to PsychoGenics for evaluation using its proprietary drug discovery technologies. The companies aim to jointly identify drug candidates suitable for clinical development. If Cephalon undertakes further development of the candidates, PsychoGenics will receive milestone payments and royalties. If PsychoGenics undertakes further dev...